# Kenneth Chien

> Kenneth Chien is a Series B investor at Moderna backing Biotechnology. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Moderna](https://shizune.co/investors/profile/moderna-therapeutics)
- Total investments: 2
- Last investment: Aug 2022
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/kenneth-chien
- Website: https://x.com/kchienmoderna

Kenneth Chien is a Series B investor at Moderna focused on Biotechnology and Health Care. Kenneth Chien is the Co-Founder of Moderna Therapeutics.

## Contacts

5 contacts available for Kenneth Chien: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/kenneth-chien?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Health Care | 1 | 50% |
| Therapeutics | 1 | 50% |
| Medical Device | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Funding Round | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Sweden | 1 | 50% |
| Belgium | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| etherna immunotherapies | eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable andsafer enhancement of the patient’s immune system than any other similar approach investigated until now. | $38.9M | Series B | Aug 23, 2022 |  |
| SmartCella | SmartCella is an innovative biotechnology and medtech company. Sweden. SmartCella’s therapeutic mission is to develop treatments for patients running out of options. The company has three main business units, Procella Therapeutics, Smartwise and SvedMed Solutions. | $37.7M |  | Sep 27, 2021 |  |

2 of 2 investments shown.

## Co-investors
- [AltoCumulus](https://shizune.co/investors/profile/altocumulus) — VC Fund, 1 deal together
- [AMF](https://shizune.co/investors/profile/amf) — VC Fund, 1 deal together
- [Fund+](https://shizune.co/investors/profile/fund) — VC Fund, 1 deal together
- Grand Pharma — VC Fund, 1 deal together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 1 deal together
- [Novalis LifeSciences](https://shizune.co/investors/profile/novalis-lifesciences) — VC Fund, 1 deal together

## About Moderna

VC Fund · Cambridge, United States

Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies insidepatient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.

5 contacts available at Moderna.

| Name | Title | Profile |
| --- | --- | --- |
| Eric Ma | Principal Data Scientist | — |
| Kenneth Chien | Co-Founder | — |
| Marcello Damiani | Chief Digital & Operational Excellence Officer | — |
| John Mendlein | President, Corporate and Product Strategy | — |
| Noubar Afeyan | Chairman & Co-Founder | — |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Kenneth Chien invest in?

Kenneth Chien invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Kenneth Chien?

Public channels for Kenneth Chien include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Kenneth Chien last invest?

The most recent investment recorded for Kenneth Chien closed in Aug 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co